FDA Warns Ferring, Says Firmagon Sales Pitch Is Misleading

Law360, Washington (April 13, 2012, 6:01 PM EDT) -- Ferring Pharmaceuticals Inc. was hit with a warning letter from the U.S. Food and Drug Administration, posted to the agency's website Friday, for making unsubstantiated claims that its prostate cancer treatment could be used as an early-stage therapy.

The letter focused on an electronic Ferring sales aid for Firmagon, which is approved to treat advanced prostate cancer. The iPad sales aid misbranded Firmagon as a preradiation, or neoadjuvant, treatment and a potential therapy for elevated prostate specific antigen, or PSA, according to the FDA.

But clinical...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.